Skip to main content
Elsevier

Epigenetic Regulation in Overcoming Chemoresistance

  • 1st Edition, Volume 16 - June 25, 2021
  • Latest edition
  • Editors: Chunfu Wu, Lihui Wang
  • Language: English

Epigenetic Regulation in Overcoming Chemoresistance, Volume 19, explains how epigenetic agents can enhance the chemotherapy sensitivity of diverse types of cancers. The book prov… Read more

Description

Epigenetic Regulation in Overcoming Chemoresistance, Volume 19, explains how epigenetic agents can enhance the chemotherapy sensitivity of diverse types of cancers. The book provides a comprehensive delineation and the recent development of the scientific studies on the epigenetic regulation in enhancing chemo-sensitivity. In addition, it discusses several topics such as DNA methyltransferase inhibitors (DNMTi), Histone deacetylases inhibitors (HDACi), Histone lysine demethylases inhibitors (HDMi), Histone lysine methyltransferases inhibitors (HMTi) and drugs regulating the microRNA, long non-coding RNA (lncRNA) or RNA methylation. Finally, recent and future developments of the field of epigenetic regulation are explored.

This is a valuable resource for cancer researchers, clinicians, graduate students and several members of biomedical field who are interested in learning about epigenetic regulation methods to reverse chemo-resistance in cancers.

Key features

  • Presents detailed diagrams of the mechanisms of epigenetic regulation for easy consult
  • Encompasses multiple clinical trial summary diagrams to help readers quickly and clearly get information from clinical trials
  • Provides future perspectives in each section to inspire readers to use epigenetic regulation to overcome chemo-resistance

Readership

Cancer researchers, medical scientists, clinicians, graduate students

Table of contents

1. The role of epigenetic regulation in cancerChunfu Wu, Lihui Wang2. DNA methyltransferase inhibitors (DNMTi) as sensitizing agents to overcome chemo-resistanceChangliang Shan, Michael J. Spinella, Ernest C. Borden3. Histone deacetylases inhibitors (HDACi) as sensitizing agents to overcome chemo-resistanceWynand Paul Roos, Nicole M. Haynes4. Histone lysine demethylases inhibitors (HDMi) as sensitizing agents to overcome chemo-resistanceHongsheng Wang, Mark A. Dawson, Petra Hamerlik5. Histone lysine methyltransferases inhibitors (HMTi) as sensitizing agents to overcome chemo-resistanceMinkui Luo, Peter Hollenhorst, Miles A. Pufall6. Drugs regulating the microRNA to overcome chemo-resistanceJasen Chen, Christoph Plass, Alex H. Mirnezami7. Drugs regulating the lncRNA to overcome chemo-resistanceMartin J. Walsh, Eleonora Leucci, ManelEstelle8. Drugs regulating the mRNA methylation to overcome chemo-resistanceYanhong Shi, Suyun Huang, Patricia L.M. Dahia, Gregg L. Semenza9. Future combined epigenetic therapyDayue Darrel Duan, Michael Lubbert, ManelEsteller

Product details

  • Edition: 1
  • Latest edition
  • Volume: 16
  • Published: June 26, 2021
  • Language: English

About the editors

CW

Chunfu Wu

Chunfu Wu，PhD, graduated from Shenyang Pharmaceutical University in 1982 and received his PhD from Hokkaido Pharmaceutical University in 2000. In 1996, he was named Professor at Department of Pharmacology of Shenyang Pharmaceutical University. Professor Wu has presided over several major scientific research projects, including the “National High-technology Research and Development Program”, and the “National Natural Science Foundation”. Besides, he has published more than 300 articles in international peer reviewed journals. Furthermore, Professor Wu has done a lot of research in the field of cancer chemo-sensitization, especially the cancer-related epigenetic regulation.Chunfu Wu，PhD, graduated from Shenyang Pharmaceutical University in 1982 and received his PhD from Hokkaido Pharmaceutical University in 2000. In 1996, he was named Professor at Department of Pharmacology of Shenyang Pharmaceutical University. Professor Wu has presided over several major scientific research projects, including the “National High-technology Research and Development Program”, and the “National Natural Science Foundation”. Besides, he has published more than 300 articles in international peer reviewed journals. Furthermore, Professor Wu has done a lot of research in the field of cancer chemo-sensitization, especially the cancer-related epigenetic regulation.
Affiliations and expertise
Professor, Department of Pharmacology, Shenyang Pharmaceutical University

LW

Lihui Wang

Lihui Wang, PhD, obtained his PhD in Pharmacology from Shenyang Pharmaceutical University in 2006. After that, Dr Wang started his investigation in the same institute, where he was promoted to full professor in 2018. From 2016 spring to 2017 summer, Dr. Wang majors in anti-cancer drug researches and went to Memorial Sloan Kettering Cancer Center in New York as a visiting investigator. Dr. Wang has published more than 20 papers, as first or corresponding author, in international peer reviewed journals, and his research focus is anti-cancer drugs development and chemo-sensitization.
Affiliations and expertise
Professor, Shenyang Pharmaceutical University

View book on ScienceDirect

Read Epigenetic Regulation in Overcoming Chemoresistance on ScienceDirect